Latest Dialysis News

ChemoCentryx Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal Association - European Dialysis and Transplant Association CongressMOUNTAIN VIEW, Calif., May 26, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI), today announced the presentation of results from the Company's development program for CCX168, an investigational orally administered inhibitor of the complement anaphylatoxin receptor known as C5aR. CCX168 is currently in a multinational, randomized, double-blind, placebo-controlled Phase II clinical trial...

Baxter's Low Glucose PD Solutions Favorably Impacted Metabolic Measures Including Glycemic Control in Trials of Diabetics Undergoing DialysisPARIS, France (May 25, 2012) — Baxter International Inc. (NYSE: BAX) today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measure...

Baxter’s Low Glucose PD Solutions Favorably Impacted Metabolic Measures Including Glycemic Control in Trials of Diabetics Undergoing DialysisBaxter International Inc. (NYSE: BAX) today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids (fats and chol...

Peritonitis commonly arises in the weeks before many dialysis patients dieAn infection called peritonitis commonly arises in the weeks before many dialysis patients die, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

Infections may be deadly for many dialysis patientsAn infection called peritonitis commonly arises in the weeks before many dialysis patients die, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings suggest that peritonitis may...

Peritonitis May Contribute to Deaths in Peritoneal DialysisPeritonitis is 6 times more common before death in peritoneal dialysis. Medscape Medical News

FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System OneLAWRENCE, Mass., May 24, 2012 /PRNewswire/ -- NxStage ® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the latest interim findings from its FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study, which found daily home hemodialysis treatments with the NxStage System One™ are associated wi...

Dialysis Patient Citizens Announces New President of the Board of DirectorsWASHINGTON, May 24, 2012 /PRNewswire-USNewswire/ -- Dialysis Patient Citizens (DPC) is proud to announce Eric Edwards has been named President of the DPC Board of Directors. Edwards, a longtime advocate for kidney disease patients, has been a DPC Board Member since 2010. "I am honored and excited to take on this new opportunity. I have always felt my purpose on Earth has been to...

The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care

Early initiation of peritoneal dialysis in neonates and infants with acute kidney injury following cardiac surgery is associated with a significant decrease in mortality

FMCNA announces new educational resources to enhance RightStartFresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, announced today new educational resources to enhance RightStart™, its innovative program designed to educate and empower new dialysis patients.

Fresenius Medical Care Launches Expanded Dialysis Patient Education InitiativeFresenius Medical Care North America (FMCNA), the nation’s leading network of dialysis facilities, announced today new educational resources to enhance RightStart™, its innovative program designed to educate and empower new dialysis patient

Since the Dialysis Bundle Legislation Was Implemented in January 2011, Bundling Appears to Have Limited Impact on Medications Used for Dialysis Patients According to a Recent BioTrends Chart StudyBioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, announces the release of its 2012 ChartTrends®: Bone and Mineral Metabolism in Dialysis (U.S.) report, the seventh in an ongoing annual series. The study was conducted with 226 U.S. nephrologists who completed detailed chart reviews...

Zytoprotec Completes Phase I/II Trial of Novel Dialysate, Enters Into Negotiations with Global ...

Vienna, Austria, May 23, 2012 / B3C newswire / – Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure. “This randomized cross-over trial has shown that PD-protec™ is...

Billion-dollar Davita deal highlights movement toward mergers, accountable care organizationsThis particular deal, in which DaVita will acquire HealthCare Partners, will enable the dialysis services provider to offer a more integrated group of services that fall under the ACO model that the government is trying to encourage.

Full results on risks of epoetin emerge 14 years after major dialysis studyMore than 14 years after the publication of a major clinical trial of the use of epoetin alfa in patients undergoing haemodialysis, a new analysis of contemporaneous data obtained under the US...

TEXT-S&P affirms DaVita Inc ratingsOverview -- Standard & Poor's Ratings Services is affirming its 'BB-' corporate credit rating on DaVita Inc., a Denver-based provider of dialysis services, in light of its plan to acquire Torrance, Calif.-based HealthCare Partners LLC (HC...

Undaunted by Wall Street “Penalty Box,” Keryx Focuses on Kidney DrugOn April 2, shares of New York-based Keryx Pharmaceuticals (NASDAQ: KERX) fell a stomach-churning 65 percent to $1.74 after the company announced that a late-stage trial of its colon cancer drug failed. But CEO Ron Bentsur was unfazed. In fact, he wa...

ASH Annual Scientific Meeting Features Several Late-Breaking PresentationsNEW YORK, May 22, 2012 /PRNewswire/ -- The 27th Annual Scientific Meeting of the American Society of Hypertension (ASH) will feature presentations of several late-breaking clinical trials, which will highlight the most recent advances in hypertension research. Dr. George Bakris, The University of Chicago Medicine and President of ASH, will present research on a new Hypoxia-inducible Factor...

Dialysis Firm Bets on Branching OutDialysis provider DaVita agreed to buy doctor-network operator HealthCare Partners in a cash-and-stock deal valued at about $4.42 billion.

UPDATE 3-DaVita looks to new healthcare model with $4.42 bln dealMay 21 (Reuters) - DaVita Inc, the biggest U.S. operator of dialysis clinics, sought to better align itself with government efforts to cut healthcare costs with a $4.42 billion deal to buy HealthCare Partners, an operator of physician practices.

DaVita to buy HealthCare Partners in $4.42B dealKidney dialysis services provider DaVita Inc. said Monday that it has agreed to buy the doctor network operator HealthCare Partners in a cash-stock deal worth about $4.42 billion.Denver-based DaVita said it will pay about $3.66 billion in cash and c...

Defense researchers work on blood-cleaning device for sepsisThe Defense Advanced Research Project Agency is developing a dialysis-like device to remove sepsis-causing agents from the bl -More-

Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA CongressNEW YORK, May 21, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that an abstract highlighting the dose related increases in iron storage parameters as observed in prior clinical trials of Zerenex™ (ferric citrate), has been accepted for poster presentation at the upcoming 49th ERA-EDTA (European Renal Association – European Dialysis and Tran...

DaVita and HealthCare Partners Announce Merger AgreementDaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), and HealthCare Partners, the country’s largest operator of medical groups and physician networks, announced today that they have entered into a definitive merger agreement. The two companies expect to close the transaction ear...

0 1 2 3 4 ›»

buy Dialysis market research data and corporate reports now Advertisement